Point mutations in the paramyxovirus f protein that enhance fusion activity shift the mechanism of complement-mediated virus neutralization

Journal of Virology

Volumn 87, Issue 16, 2013, Pages 9250-9259

  Johnson, John B ^a   Schmitt, Anthony P ^b   Parks, Griffith D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GLYCINE; SERINE; VIRUS FUSION PROTEIN;

ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PARAINFLUENZA VIRUS 5; PARAMYXOVIRUS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SURFACE PROPERTY; VIRION; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RECOMBINANT; WILD TYPE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; COMPLEMENT SYSTEM PROTEINS; DNA MUTATIONAL ANALYSIS; HUMANS; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, IMMUNOELECTRON; MUTANT PROTEINS; NEUTRALIZATION TESTS; PARAMYXOVIRINAE; POINT MUTATION; VIRAL FUSION PROTEINS; VIRAL PLAQUE ASSAY; VIRUS INTERNALIZATION;

EID: 84881241292     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01111-13     Document Type: Article

References (46)

1. Blue CE, Spiller OB, Blackbourn DJ. 2004. The relevance of complement to virus biology. Virology 319:176-184.
2. McSharry JJ, Pickering RJ, Caliguiri LA. 1981. Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid. Virology 114:507-515.
3. Devaux P, Christiansen D, Plumet S, Gerlier D. 2004. Cell surface activation of the alternative complement pathway by the fusion protein of measles virus. J. Gen. Virol. 85:1665-1673.
4. Gasque P. 2004. Complement: a unique innate immune sensor for danger signals. Mol. Immunol. 41:1089-1098.
5. Stoermer KA, Morrison TE. 2011. Complement and viral pathogenesis. Virology 411:362-373.
6. Johnson JB, Lyles DS, Alexander-Miller MA, Parks GD. 2012. Virionassociated CD55 is more potent than CD46 in mediating resistance of mumps virus and VSV to neutralization. J. Virol. 86:9929-9940.
7. Johnson JB, Grant K, Parks GD. 2009. The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization. J. Virol. 83:7602.
8. Carroll MC. 2004. The complement system in regulation of adaptive immunity. Nat. Immunol. 5:981-986.
9. Roozendaal R, Carroll MC. 2006. Emerging patterns in complementmediated pathogen recognition. Cell 125:29-32.
10. Ebenbichler CF, Thielens MN, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP. 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174:1417-1424.
11. Beebe DP, Cooper NR. 1981. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126:1562-1568.
12. Gunn BM, Morrison TE, Whitmore AC, Blevins LK, Hueston L, Fraser RJ, Herrero LJ, Ramirez R, Smith PN, Mahalingam S, Heise MT. 2012. Mannose binding lectin is required for alphavirus-induced arthritismyositis. Plos Pathog. 8(3):e1002586. doi:10.1371/journal.ppat.1002586.
13. Hartshorn KL, Sastry K, White MR, Anders EM, Super M, Ezekowitz RA, Tauber AI. 1993. Human mannose-binding protein functions as an opsonin for influenza A viruses. J. Clin. Invest. 91:1414-1420.
14. Pangburn MK, Schreiber RD, Müller-Eberhard HJ. 1981. Formation of the initial C3 convertase of the alternative pathway: Acquisition of C3blike activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 154:856-867.
15. Mold C, Bradt BM, Nemerow GR, Cooper NR. 1988. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350. J. Immunol. 140:3867-3874.
16. Hirsch RL, Winkelstein JA, Griffin DE. 1980. The role of complement in viral infections. III. Activation of the classical and alternative complement pathways by Sindbis virus. J. Immunol. 124:2507-2510.
17. Joseph BS, Cooper NR, Oldstone MBA. 1975. Immunologic injury of cultured cells infected with measles virus. I. Role of IgG antibody and the alternative pathway. J. Exp. Med. 141:761-774.
18. Biswas M, Kumar S, Johnson JB, Parks GD, Subbiah E. 2012. Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J. Virol. 86:12708-12716.
19. Lamb RA, Parks GD. 2007. Paramyxoviridae: the viruses and their replication, p 1449-1496. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
20. Hirsch RL, Wolinsky JS, Winkelstein JA. 1986. Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity. Arch. Virol. 87:181-190.
21. Chang A, Dutch RE. 2012. Paramyxovirus fusion and entry: multiple paths to a common end. Viruses 4:613-636.
22. Lamb RA, Paterson RG, Jardetzky TS. 2006. Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology 344:30-37.
23. Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS. 2006. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38-44.
24. Paterson RG, Shaughnessy MA, Lamb RA. 1989. Analysis of relationship between cleavability of paramyxovirus fusion protein and length of connecting peptide. J. Virol. 63:1293-1301.
25. Horvath CM, Lamb RA. 1992. Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: roles of conserved residues in cell fusion. J. Virol. 66:2443-2455.
26. Paterson RG, Russell CJ, Lamb RA. 2000. Fusion protein of the paramyxovirus SV5: destabilizing and stabilizing mutants of fusion activation. Virology 270:17-30.
27. Russell CJ, Jardetzky TS, Lamb RA. 2004. Conserved glycine residues in the fusion peptide of the paramyxovirus fusion protein regulate activation of the native state. J. Virol. 78:13727-13742.
28. He B, Paterson RG, Ward CD, Lamb RA. 1997. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237: 249-260.
29. Gainey MD, Manuse MJ, Parks GD. 2008. Hyperfusogenic F protein enhances oncolytic potency of an SV5 P/V mutant without compromising sensitivity to type I interferon. J. Virol. 82:9369-9380.
30. Waning DL, Russell CJ, Jardetzky TS, Lamb RA. 2004. Activation of a paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic tail. Proc. Natl. Acad. Sci. U. S. A. 101:9217-9222.
31. Johnson JB, Capraro GA, Parks GD. 2008. Differential mechanisms of complement mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology 376:112-123.
32. Connolly SA, Leser GP, Yin HS, Jardetzky TS, Lamb RA. 2006. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc. Natl. Acad. Sci. U. S. A. 103:17903-17908.
33. Macher BA, Galibi U. 2008. The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim. Biophys. Acta 1780:75-88.
34. Welsh RM, O'Donnell CL, Reed DJ, Rotther RP. 1998. Evaluation of the Galα1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J. Virol. 72:4650-4656.
35. Randall RE, Young DF, Goswami KK, Russell WC. 1987. Isolation and characterization of monoclonal antibodies to simian virus 5 and their use in revealing antigenic differences between human, canine and simian isolates. J. Gen. Virol. 68:2769-2780.
36. Jayasekera JP, Moseman EA, Carroll MC. 2007. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J. Virol. 81:3487-3494.
37. Vasantha S, Coelingh KL, Murphy BR, Dourmashkin RR, Hammer CH, Frank MM, Fries L. 1988. Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. Virology 167:433- 441.
38. Tsurudome M, Ito M, Nishio M, Kawano M, Komada H, Ito Y. 2001. Hemagglutinin-neuraminidase-independent fusion activity of simian virus 5 fusion (F) protein: difference in conformation between fusogenic and nonfusogenic F proteins on the cell surface. J. Virol. 75: 8999-9009.
39. Aguilar HC, Matreyek KA, Filone CM, Hashimi ST, Levroney EL, Negrete OA, Bertolotti-Ciarlet A, Choi DY, McHardy I, Fulcher JA, Su SV, Wolf MC, Kohatsu L, Baum LG, Lee B. 2006. N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J. Virol. 80:4878-4889.
40. Ader N, Brindley M, Avila M, Örvell C, Horvat B, Hiltensperger G, Schneider-Schaulies J, Vandevelde M, Zurbriggen A, Plemper RK, Plattet P. 2013. Mechanism for active membrane fusion triggering by morbillivirus attachment protein. J. Virol. 87:314-326.
41. Porotto M, Palmer SG, Palermo LM, Moscona A. 2012. Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry. J. Biol. Chem. 287:778-793.
42. Farzan SF, Palermo LM, Yokoyama CC, Orefice G, Fornabaio M, Sarkar A, Kellogg GE, Greengard O, Porotto M, Moscona A. 2011. Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery. J. Biol. Chem. 286:37945-37954.
43. Seth S, Goodman AL, Compans RW. 2004. Mutations in multiple domains activate paramyxovirus F protein-induced fusion. J. Virol. 78:8513-8523.
44. Young DF, Didcock L, Randall RE. 1997. Isolation of highly fusogenic variants of simian virus 5 from persistently infected cells that produce and respond to interferon. J. Virol. 71:9333-9342.
45. Chang G, Xu S, Watanabe M, Jayakar HR, Whitt MA, Gingrich JR. 2010. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. J. Urol. 183:1611-1618.
46. Nayak S, Herzog RW. 2010. Progress and prospects: immune responses to viral vectors. Gene Ther. 17:295-304.